Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
REGENXBIO logo — Seeking to improve lives through the curative potential of g...

REGENXBIO

Seeking to improve lives through the curative potential of gene therapy.

Founded 2008 United States Rockville, United States 389 employees IPO Total: $1.58B Biopharma, Biotechnology +1

General Information

Company Name REGENXBIO
Founded Year 2008
Location United States Rockville, United States
Employees 389
Industries Biopharma, Biotechnology, Health and Wellness
Funding Stage IPO
Business Model B2B
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with REGENXBIO. To contact REGENXBIO, visit regenxbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does REGENXBIO compare?

A PDF of REGENXBIO and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting REGENXBIO soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About REGENXBIO

REGENXBIO, founded in 2008, is a clinical-stage biotechnology company based in the United States known for its pioneering work in AAV Therapeutics, a promising class of gene therapy medicines. The company is actively advancing a robust pipeline targeting retinal and rare diseases with products like ABBV-RGX-314 in collaboration with AbbVie, RGX-202 for Duchenne, and RGX-121 for MPS II. These treatments, potentially one-time therapies, could revolutionize healthcare for millions globally.

With its innovative platform, REGENXBIO has impacted thousands of patients, including those treated with Novartis’ ZOLGENSMA for spinal muscular atrophy. The company is continually attracting substantial investments, most recently securing a $250.00M post-IPO debt financing from HealthCare Royalty Partners as of 01 May 2025. This investment positions REGENXBIO for promising future growth in the biopharma and biotechnology sectors.

Business keywords: Gene Therapy, AAV Therapeutics, Biopharmaceuticals, Retinal Diseases, Rare Diseases, AAV Vectors, Metabolic Disorders, Muscle Diseases, Hematologic Disorders, Ocular Diseases, Neurodegenerative Disorders, One-time Treatments, Therapeutic Development, Reagent Services

Services & Products

Developing Gene Therapy Candidates
Clinical Trials
In-house Manufacturing
Research and Development

Target Customers

Patients with Retinal Diseases Patients with Genetic Disorders Healthcare Providers Pharmaceutical Partners

Funding Rounds & Investors (17)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt $250.00M 1
HealthCare Royalty Partners
HealthCare Royalty Partners
01 May 2025
Post-IPO Debt $250.00M 1
HealthCare Royalty Partners
HealthCare Royalty Partners
01 May 2025
Post-IPO Equity $150.00M -
01 Dec 2024
Post-IPO Equity $150.00M -
01 Dec 2024
Post-IPO Equity $140.00M -
01 Mar 2024
Post-IPO Equity $230.30M -
01 Jan 2021
Post-IPO Equity Undisclosed 1
Frazier Healthcare Partners
Frazier Healthcare Partners
01 Jan 2020
Post-IPO Equity $201.80M -
01 Aug 2018
Post-IPO Equity $87.20M -
01 Mar 2017
IPO Undisclosed -
01 Sep 2015

View All 17 Funding Rounds

REGENXBIO Alternatives & Competitors

View All Alternatives
REGENXBIO vs
AskBio Inc.
AskBio Inc. United States

Pioneering science to create transformative molecular medicines.

Grant
526 employees
Biopharma, Biotechnology
Compare REGENXBIO vs AskBio Inc.
REGENXBIO vs
AAVantgarde
AAVantgarde

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease

Series A
70 employees
Biotechnology, Health Care
Compare REGENXBIO vs AAVantgarde
REGENXBIO vs
Bloomsbury Genetic Therapies
Bloomsbury Genetic Therapies United Kingdom

Dedicated to delivering the promise of gene therapy

Seed
2 employees
Biopharma, Biotechnology
Also compare with: REGENXBIO vs Vivet Therapeutics Vivet Therapeutics View all alternatives

FAQ About REGENXBIO

Seeking to improve lives through the curative potential of gene therapy.
REGENXBIO was founded in 2008.
REGENXBIO is headquartered in Rockville, United States.
REGENXBIO operates in Biopharma, Biotechnology and Health and Wellness. Its work centres on Gene Therapy, AAV Therapeutics, Biopharmaceuticals and Retinal Diseases. Its customers include Patients with Retinal Diseases, Patients with Genetic Disorders and Healthcare Providers.
REGENXBIO has a B2B business model. Its revenue comes from Licensing, Product Sales and Performance Based.
REGENXBIO has approximately 389 employees.
REGENXBIO has completed 17 funding rounds, raising a total of $1.58B. The latest funding stage is IPO.
REGENXBIO offers: Developing Gene Therapy Candidates, Clinical Trials, In-house Manufacturing, Research and Development.
Top alternatives and competitors to REGENXBIO include AskBio Inc., AAVantgarde, Bloomsbury Genetic Therapies, Spark Therapeutics, Inc., Vivet Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
REGENXBIO and AskBio Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for REGENXBIO, https://bouncewatch.com/company/regenxbio-inc, updated 20 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout